News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Lipodystrophy
Mark S. King: I'm Gonna Wipe That AIDS Right Off My Face

It was all well and good to be front and center as an HIV-positive man during the first years of the AIDS crisis. It's easier being a role model when your face looks good on the poster. But then, slowly but surely, a common side effect of HIV medications, facial wasting, began to appear.

Published
30 January 2013
From
Huffington Post
Side-effects
Systematic review confirms that efavirenz is a safer option than nevirapine for adults and children starting HIV therapy

Efavirenz is a safer option than nevirapine for adults and children starting antiretroviral therapy, according to the results of a meta-analysis published in the online edition of

Published
29 January 2013
By
Michael Carter
Outcomes and prognosis
Australian researchers project that many HIV-positive people will run out of treatment options

Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in

Published
22 January 2013
By
Michael Carter
Side-effects
Large study shows the hepatic safety of HIV therapy

Results from a large study published in the online edition of Clinical Infectious Diseases provide reassurance about the hepatic safety of antiretroviral drugs. Investigators from the D:A:D study

Published
22 January 2013
By
Michael Carter
Side-effects
Treatment with raltegravir increases the risk of mild muscular side-effects

Treatment with the HIV integrase inhibitor raltegravir (Isentress) is associated with an increased risk of skeletomuscular side-effects, according to Australian research published in the online edition of the

Published
14 January 2013
By
Michael Carter
Neurological and cognitive problems
Neuropathy and HIV: A Progress Report

Neuropathy affects up to 40% of all people with HIV, yet the treatment has remained more or less the same for decades. Prescribing drugs meant for other diseases, has led to haphazard results; time for a change - but is it happening?

Published
11 January 2013
From
PositiveLite
Side-effects
FDA clears Salix anti-diarrhoeal for HIV patients

The US Food and Drug Administration has approved the first anti-diarrhoeal drug specifically for people with HIV, Salix Pharmaceuticals Ltd.'s Fulyzaq. The drug, also known as crofelemer, is meant to relieve symptoms of noninfectious diarrhoea in people with HIV on antiretroviral therapy. Fulyzaq is derived from the red sap of the Croton lechleri plant and is the second botanical prescription drug approved by the FDA. However, although crofelemer produced a 55% reduction in watery diarrhoea in people with HIV on ART who chronically suffered from it, this only means that 17.6% of patients improved during the study period rather than 8% given a placebo.

Published
02 January 2013
From
MarketWatch
Prevention of mother-to-child transmission
Treatment with a protease inhibitor during the first trimester of pregnancy increases the risk of pre-term birth

Further evidence has emerged from research in the United States that antiretroviral therapy based on a protease inhibitor (PI) during the first three months of pregnancy

Published
18 December 2012
By
Michael Carter
Cardiovascular disease
HIV11: Lipid Levels Are Higher among HIV+ People on ART, Immune Suppression May Play a Role

People with HIV on suppressive antiretroviral therapy (ART) have "considerably higher" blood lipid levels relative to untreated individuals or those on less effective treatment, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) last month in Glasgow. They also found that greater immune deficiency, as indicated by lowest-ever CD4 count, was associated with lipid elevations.

Published
17 December 2012
From
HIVandhepatitis.com
Side-effects
Low-dose stavudine study debated between South African researchers and activists

A proposed trial of low-dose stavudine (also known as d4T) sparked a heated debate between South African researchers and activists at the opening of the first Southern

Published
11 December 2012
By
Lesley Odendal
← Prev12345...65Next →

Filter by country